Very recently, the KRASG12C inhibitor sotorasib and the MAP2K4 inhibitor HRX-0233 were shown to synergistically inhibit growth of a number KRAS mutant CRC and lung cancer cell lines and to induce durable tumor shrinkage in mouse xenografts of human lung cancer cells67. This evidence concerns the gene MAP2K4 and neoplasm.